BioMedGPS announces expanded coverage of SmartTRAK Business Intelligence in the realm of Robotic and Computer Assisted Surgery with the launch of its first module, US Computer Assisted Surgery (CAS) – Spine at the upcoming NASS conference later this month. A second SmartTRAK module, US Computer Assisted Surgery (CAS) – Ortho, will be introduced at the American Associate of Hip and Knee Surgeons (AAHKS) meeting in November.
Extremities market experiences slight gains due to expanded product portfoliosThe US Extremities Market experienced a slight gain in Q218 according to SmartTRAK Financial Dashboard, slightly lower than the rate anticipated in the US Extremities Market Overview. We anticipate the Extremities segment rebounding to achieve...
Among the many topics covered in the Q218 Extremities Market Recap are:
- Competition in Shoulders Heating Up
- Expanded Portfolios and Awareness Driving Continued Ankle Growth
- Extremities Fixation: Company Focus and New Product Intros Incite Growth
- Regulatory Highlights
SmartTRAK discusses the current and future state of ankle replacement in the United States including current trends in the market and how ankle replacement may evolve in an interview with Steven Haddad, MD, Senior Attending Physician, Illinois Bone and Joint Institute.
Among the many topics covered Q218 Trauma Market Recap are:
BioMedGPS, a leading provider of real-time data and analysis in the orthopedic, wound care and neuro therapies markets, is pleased to welcome Amanda Tracy into the role of Chief Commercial Officer. Joining the BioMedGPS leadership team, Ms. Tracy will be responsible for overseeing all sales and marketing initiatives for the company’s highly regarded SmartTRAK Business Intelligence platform.Ms. Tracy brings with her over 22 years of experience in sales, marketing and business development in both the medical device and pharmaceutical industries. Along with the many relationships she has fostered within the industry, Ms. Tracy brings a unique understanding of the musculoskeletal clinical, regulatory and reimbursement landscapes and the value of integration with each. Prior to joining BioMedGPS, Ms. Tracy worked for 10 years at Musculoskeletal Clinical Regulatory Advisors (MCRA), where she attained the position of Vice President, Global Market Development and was responsible for growing MCRA’s revenues from $100K to $20 million.
“I am delighted to have such a high caliber and seasoned professional as Amanda Tracy lead our commercial efforts,” reports Sharon O’Reilly, President and CEO of BioMedGPS. “Amanda has the breadth of experience and proven expertise needed to bring BioMedGPS to the next level.”
Irrespective of Market Challenges, Orthobiologics Remain Strong
While SmartTRAK saw a strong start in the beginning of the year, Orthobiologics didn’t see the typical Q2 bump. This trend was primarily driven by lower bone replacement revenues. Revenues from the sports medicine segments partially offset the bone replacement declines, with strong performances in Cartilage Replacement and Soft Tissue Augmentation.
Among the many topics covered in the full Q218 Ortho Market Recap are:
Baxter, Ethicon and Integra lead the way...As reported in SmartTRAK’s Financial Dashboard, the US market for Hemostats and Sealants grew +3.8% YoY in Q218, an increase from +3.1% growth rate overall in Q118. Fibrin sealants continue to lead the way with +7.2% YoY growth in Q218, and thrombin hemostats had a very good quarter with +7.2% growth YoY...
Among the many topics covered in the full Q218 Hemostats and Sealants Market Recap are:
- Ethicon Continues to Lead Hemostats and Sealants
- Thrombins Come Back In Hemostats
- Fibrin Continues To Shine In Sealants
- Q218 events in the US Hemostats and Sealants Market
Volume Up, Pricing Down, Overall Market Lower
Now that Q218 results are in, the US Joint Fluid market continued to experience downward pressure posting negative growth of -6.5% for the quarter and -4.0% YTD, according to SmartTRAK Financial Dashboard results ...
Topics: Joint Fluid
Cerapedics’ CEO Glen Kashuba and President and COO Jeff Marx, Ph.D. discuss the future of the bone graft substitutes and the uniqueness of i‑FACTOR Peptide Enhanced Bone Graft, a small peptide technology in an interview with Kim French, Sr. Analyst, SmartTRAK Orthbio.
A transcript of SmartTRAK's interview with Glen Kashuba and Jeff Marx is below, or click on the following video to listen to the interview.
With SmartTRAK, you will always be ahead of the competition.
We just launched SmartTRAK 3.0, the latest version of our premier Business Intelligence Data Platform in the Orthopedics, Wound Care and Neuro Therapies spaces.
Topics: SmartTRAK 3.0